RCM
CEROW

Robinson Capital Management’s CERo Therapeutics Warrants CEROW Stock Holding History

Robinson Capital Management’s Portfolio CEROW Stock Details CEROW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-355
Closed -$3 – 157
2024
Q3 		$3 Hold
355
– – ﹤0.01% 215
2024
Q2 		$7 Buy
+355
New +$21 ﹤0.01% 202
2024
Q1 		– Sell
-1,000
Closed -$24 – 193
2023
Q4 		$24 Sell
1,000
-112
-10% -$3 ﹤0.01% 211
2023
Q3 		$80 Sell
1,112
-6,304
-85% -$451 ﹤0.01% 225
2023
Q2 		$336 Buy
7,416
+3,673
+98% +$159 ﹤0.01% 227
2023
Q1 		$112 Hold
3,743
– – ﹤0.01% 278
2022
Q4 		$161 Hold
3,743
– – ﹤0.01% 315
2022
Q3 		$0 Buy
3,743
+478
+15% +$40 ﹤0.01% 324
2022
Q2 		$0 Buy
+3,265
New +$526 ﹤0.01% 327

Other funds holding CEROW

CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
CSD
Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Robinson Capital Management's CEROW Position: Q4 2024 in Review

Robinson Capital Management sold out of CERo Therapeutics Warrants (CEROW) in Q4 2024, closing a stake of 355 shares — an estimated $3 sold.

Robinson Capital Management first reported a position in CEROW in Q2 2022 and held it in 9 quarters. The position peaked at $336 in Q2 2023. 26 funds tracked by Wall St. Rank hold CEROW as of Q4 2024.

  • Robinson Capital Management reported no remaining CERo Therapeutics Warrants position as of Q4 2024 after selling out during the quarter.
  • Robinson Capital Management sold 355 CERo Therapeutics Warrants shares in Q4 2024, an estimated $3.
  • Robinson Capital Management first reported a position in CERo Therapeutics Warrants in Q2 2022 and held it in 9 quarters.
  • Robinson Capital Management's CERo Therapeutics Warrants position peaked at $336 in Q2 2023.
  • 26 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q4 2024.

Based on Robinson Capital Management's 13F filing for Q4 2024, filed 31 Jan 2025.